A program 100% dedicated to translational research on diabetes
Organised by the Lund University Diabetes Center, Eurasanté and the NHL Cluster, and supported by Ascenion, AstraZeneca, Novo Nordisk and Sanofi, the IDEA Summit is a unique European event entirely dedicated to collaborative research and technology transfer in the field of diabetes. The aim of this meeting is to be a platform for dialogue and strengthen links between academia and industry. We hope that exchanges and discussions at this event will stimulate collaborative research for the prevention, diagnosis and treatment of diabetes and its complications.
At IDEA Summit’s previous editions, it became clear that academia and industry made progress in understanding each other’s strengths and driving forces. However, there is still a great need to continue to develop new ways to stimulate interaction and more effective knowledge and resources sharing, and even go further and involve patients by creating sustainable links between academics and clinicians.
The different panels will provide a framework of wider discussions on bottlenecks that contribute to slow translation of diabetes research and on what can be done to bridge the existing gaps. Moreover, the partnering will give the opportunity to engage new collaborating opportunities and dialogues among the actors in this field.
EGID Symposium – 4th edition
Liver, Diabetes and Cardiovascular Risks
What is EGID?
EGID (European Genomic Institute for Diabetes) is an international research institute focused on diabetes (type 1 and 2), obesity and its associated risk factors. Its vocation is to diffuse and valorize the “research products”.
EGID is the first diabetes institute in France with an international visibility and it is the only center in the world that presents such a wide scope in its field: fundamental research, university education, permanent education, prevention, prediction, clinical applications, industrial valorization and promotion of public health actions.
EGID is destined to play a major role worldwide in the fields of diabetes, obesity and its associated factors. The fundamental mission of the institute will be to develop mayor breakthroughs in the understanding of these diseases, as well as their diagnosis and therapeutic treatments.
What does EGID symposium deal with?
The European Genomic Institute for Diabetes (EGID) organises its fourth international symposium on 29th and 30th November 2016, in Lille, FRANCE.
This 4th edition is hosted by BioFIT and organised in collaboration with IDEA Summit (www.idea-summit-diabetes.com). The committee and speakers – world leaders in their fields – will present the latest scientific advances in diabetes and related disorders. This symposium provides an opportunity for young researchers to present their work via poster presentation and to win the “Best Poster Award” of up to €1,000.
ONCOLille Days features a programme of conferences and poster presentations around oncology. Organised by the SIRIC ONCOLille, an Integrated Cancer research Consortium in Lille, supporting clinicians and researchers in the field of oncology, this event will be hosted during BioFIT 2016.
The translational research consortium ONCOLille is promoting a swift transfer between basic and clinical researches in the Lille area on two major issues of modern oncology: the tumor resistance to loco-regional treatments and the tumor dormancy (or resilience) after remission.
During the scientific symposium, the SIRIC ONCOLille Days, researchers will present their latest discoveries on the molecular mechanisms explaining the tumor cell resistance to treatment (MET receptors, MUC4-ErbB2 complexes, calcium canals involvement, immunosuppressive role of regulatory T cells…) or explaining cancer cell persistence after treatment (immune-evasion due to PD1-PDL1 interactions, tumor cell clonality…). Drug development strategies based on those finding will be discussed.
Therapeutic innovations supported by ONCOLille technological platforms will also be presented: tumor cell clonality monitoring by NGS in the acute lymphoid lymphoma, improved glioblastoma classification by mass spectrometer proteomic analyses, assisted tumor ablation with an “in situ” and “real time” mass spectrometer tool, innovative animal models (spontaneous animal models, zebra fish model…)…
ONCOLille will also have the pleasure to present the work from it Human and Social Sciences programme on the way to better assess the cancer personal experiences of patients (and relatives) and to develop psychological and therapeutic methods to improve the cancer care pathway.
- On Day 1 (30th November): Participants of the SIRIC ONCOLille Days will take part in the partnering platform of BioFIT, giving them the additional opportunity to carry out the necessary exchanges through one-to-one meetings.
- On Day 2 (1st December): Conferences and poster presentations on the latest scientific breakthroughs in the field of personalised cancer care will be displayed by leading experts.
Would you like to learn more about and register for ONCOLille Days?
Contact Maximilien VANLEENE : Maximilien.email@example.com
About the organiser: SIRIC ONCOLille
SIRIC ONCOLille is a cancer research consortium in basic, translational and clinical cancer research involving more than 20 academic and clinical research laboratories in the Lille area.
About 400 scientists and clinicians collaborate within ONCOLille to progress our understanding of modern oncology and propose new technologies and treatments through three main research programmes. These are intern supported by four integrated platforms, pooling high-tech tools and leading scientific expertise in the fields of cell and molecular biology, genetic sequencing, tumor biobanking, imaging, animal models and research methodology.
Patient care is at the heart of ONCOLille’s objectives and is improved thanks to our research programmes, which bring the latest basic, translational, clinical and HSS scientific breakthroughs to the patient’s bedside.
ONCOLille’s programmes are supported by a proactive policy to support and enlarge existing national and international collaborative networks. The consortium also fosters an active technology transfer approach towards biotechnology companies thanks to a strong partnership with the Eurasanté agency.
AFSSI Conference: Conference organised by the French Association of Outsourcing and Innovative Companies to enhance sustainable collaboration between European industrial life sciences and R&D stakeholders.
Over 100 French entrepreneurs running business in R&D Life Sciences, big company decision makers, academic research leaders, governmental regulators and investors will meet next December in Lille to design the best relationships within the new landscape of industry R&D cooperation. In the center of the topics: the growth of small and medium “technology” companies driven by the need of biopharma companies to improve research at limited cost and by the need of academic organizations to mature the output of research programs.
As a further step of the previous symposia organized by AFSSI within BioFIT 2014 & BioFIT 2015, the meeting aims at focusing to
- Highlight heavy and complementary expertise of AFSSI Members (Life Sciences R&D service providers), considered as the first French research center,
- Build sustainable relationships between industrial Life Sciences R&D stakeholders,
- Benchmark similar European R&D provider networks.
The Association Française des Sociétés de Services et d’Innovation (AFSSI) [French Association of Outsourcing and Innovative Companies] in the field of Life Sciences was born in 2012 to gather Companies established in France and providing R&D services to industrial or academic partners. It is a non-profit organization (Association Loi de 1901) headquarter in Romainville (FR-93230). AFSSI embraces the domain of Life Sciences at large: Biotechnology, Fine Chemistry, Cosmetology, Agro food, Bioinformatics, Diagnostics, Clinical trials, Green business.
AFSSI represents over 120 companies involved in a dual business model, investing a significant part of their revenues in R&D to update and broaden their technology offering in order to run research programs on behalf of third parties. They manage a long term process to support their growth.
AFSSI provides advocacy, internal relationships, communications services for the members both large and small companies.
AFSSI entrepreneurs are consistent operators of life science development known as the new frontier of industry. Thanks to their knowhow and professionalism they make easier and faster the market access of innovative products in pharmacy, cosmetology, agro-food, etc.
AFSSI challenges are driven by the vision of Life Sciences companies as top players of French international competition. AFSSI works toward enriching the Life Sciences industry with networking, partnering and education opportunities.
Organised in partnership with the BioFIT Licensing Opportunity Presentations BioFIT, TechnoMarket is an event created by Réseau SATT to discover innovative technologies from public research. It’s a real market place for companies ready to innovate. The technologies presented will be selected by an expert committee with a call for applications issued in French and European transfer structures. Meet us during the BioFIT event!
TECHNOMARKET: The meeting to discover innovative technologies
TechnoMarket offers the opportunity to detect the most promising technologies and platforms, target needs and new industrial challenges, create new exchange opportunities to enable companies to increase their development and meet the innovation network with decision makers and key partners of the industry sector.
The presentations will deal with the following categories:
- Infectiology / Vaccines
3 phases, 3 possibilities of interaction:
- Thematic expert interventions to introduce new uses and think about the way to prepare the challenges of tomorrow.
- Technologies explanation through pitch presentations or posters exhibition
- BtoB appointments to meet, exchange and deepen the addressed issues.
More information: www.technomarket.fr
RESEAU SATT: The French Technology Transfer Accelerator network
In France, SATTs have a challenging mission to accelerate the translation of research into innovations. SATTs are the privileged conduit to license emerging technologies from universities and public research centers. Their aim is to enhance the value and to accelerate the process of technology transfer from publically funded research towards industry. SATTs have become a major actor of economic development to reinforce company competitiveness, with an emphasis on SMEs and start-ups.
Key Figures. As of 31 December 2015, SATTs include:
- 14 active SATT organisations
- 473 highly qualified professionals
- 5500 disclosures evaluated
- 1184 priority patent applications filed
- 349 license agreements
- 106 start-up
More information: www.satt.fr